Leonard Minuk

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 849 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Hartmut Goldschmidt, Rubén Niesvizky et al. · The Lancet Oncology · 2017 · 401 citations

Medicine, Oncology, Pharmacology +14

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide

Michel Delforge, Leonard Minuk, J.-C. Eisenmann et al. · Haematologica · 2015 · 90 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 47 citations

Medicine, Oncology, Pharmacotherapy +12

Decreased hepatocyte membrane potential differences and GABAa-β3 expression in human hepatocellular carcinoma

Gerald Y. Minuk, Manna Zhang, Yuewen Gong et al. · Hepatology · 2007 · 44 citations · Full text

Medicine, Molecular Biology, Oncology +17